2015 Winter Symposium

Jane has over 22 years of clinical hematology and oncology experience. Jane leverages de-identified patient level data to aid in disease modelling, health outcomes research and therapeutic forecasting. Jane works with clients from pre-clinical development through post marketing safety and surveillance. Jane’s work with de-identified patient level data has been published in The Journal of the National Comprehensive Cancer Network, The Journal of Oncology, ESMO/ECCO, ASCO, ASH, and SABCS.

Prior to joining IMS, Jane was the Vice President of Business Development at IntrinsiQ LLC. While at IntrinsiQ Jane expanded their clinical consulting capabilities and worked extensively with the Financial sector, including Goldman Sachs, Rodman & Renshaw, and Sanford Bernstein. Jane was the Clinical Nurse Specialist for the Division of Hematology/Oncology at Georgetown-The Lombardi Cancer Center, Director of Bone Marrow Transplantation and PBSCT. Jane is a member of ASCO and ONS. She has a BSN from Georgetown University.

Healthcare is among the first industries to generate a wealth of information. For manufacturers and service providers, that information has repeatedly shaped marketing initiatives. The breadth and depth of available information continues to evolve, yet the key to optimization of the new data sources has yet to be discovered. As sales and marketing professionals, it is imperative that we understand what data is available to us now and in the future, as well as how our organizations can benefit.

The 2015 PMSA Symposium in Austin, TX will feature a hands-on workshop on the emerging EMR data. Though EMR data is not entirely a new notion, it’s use for marketing initiatives has been quickly gaining popularity. Though outcomes research professionals have arguably adopted the use of this data at a faster pace, the ability to gain insights not available in traditional claims datasets is highly sought after, in markets such as oncology. Sources of EMR data continue to grow and a marketer must consider the benefits and caveats of each.

Although all datasources have their drawbacks, EMRs have the potential to replace traditional primary research. A prime candidate for cannibalization are the traditional chart audit studies. Physician recall bias, sample sizes, costs and result times are among the potential reasons that primary research may soon be replaced by analyses of EMR datasets.

Come learn more about EMR data in marketing and see how it can change the way you obtain insights.

Specialty Pharmacy (SP) Data, the data associated with the products sold through specialty pharmacies and specialty pharmacy distributors, is growing to be one of the most important pieces of pharmaceutical data elements. For a variety of reasons, many of these data sets do not get acquired and built into the ‘traditional’ data products offered by major data vendors. This has created a burden on the commercial operations and analytics departments of bio/pharma companies, forcing many of them to acquire, cleanse and integrate these data in-house. Hence, the management and curation of this ever increasing big data will be of paramount importance.

In this presentation, Axtria will lay out the business best practices which we have developed through our expertise in helping our clients manage their SP data. We will showcase how a big data, cloud-based platform integrates Data Quality Management, Master Data Management and Data Integration Management to help bio-pharma companies convert raw data from Specialty Pharmacies into meaningful information for use in multiple-downstream commercial operations and analytic decision-making.

As an industry, the answers to many of our unresolved questions will require combining disparate data streams – at a deterministic, patient-level – to create a more complete and more useful understanding of the clinical narrative. The following presentation will demonstrate the value of a Linked Electronic Health Record (EHR) – Claims dataset through one particularly unique application: primary adherence.

Given the silos of data, nearly all adherence studies focus on behavior that occurs after a patient fills a prescription at the pharmacy. Anecdotally, we know that many patients never make it to the pharmacy after receiving a prescription. Using our linked EHR – Claims dataset, we can measure the leakage between the prescription and the pharmacy, defining the rate at which patients fill a medication as prescribed by the provider as primary adherence. In this case study, we will discuss methods to analyze primary adherence, as well as the clinical and business impact of primary non-adherence for both pharmaceutical manufacturers and the healthcare system at large.

Presenting insights gained from three distinct implementations and uses of population health solutions by integrated delivery networks (IDNs). Interoperability, coupled with the utilization of population health tools, is what has separated Unity Health System (UHS), Citrus Valley Health Partners (CVHP) and University of Pittsburgh Medical Center (UPMC) from the rest of the pack. This presentation will summarize the population health processes employed to collect patient data and identify insights gained by physicians, enabling them to take action and improve patient outcomes.